NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 6 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Vijaya Diagnostic Reports 26.7% YoY Q2 Revenue Growth at ₹255 Cr; Plans 6 More Hubs by Q1 FY28
Vijaya Diagnostic Centre released its Q2 FY27 earnings conference call transcript, highlighting a consolidated revenue growth of 26.7% YoY to ₹255 crore, driven by a 16.5% volume growth. Consolidated EBITDA rose to approximately ₹113 crore compared to ₹82 crore in the prior-year period. The company added 2 hubs and 7 spokes in H1 FY27, with plans to commission 3 more hubs in H2 FY27 and 3 in Q1 FY28. Additionally, the company entered the Northeast region by signing an agreement to acquire Arya Wellness Centre in Guwahati.
உச்சம் நம்பிக்கை
என்ன மாறியதுVijaya Diagnostic published its detailed Q2 FY27 earnings conference call transcript following the quarterly results declaration.
ஏன் இது முக்கியம்Demonstrates robust core market performance in Hyderabad (>20% YoY growth) and accelerating expansion into new territories like Bengaluru and Northeast India with high EBITDA margins.
📅 குறுகிய காலம்Market sentiment should stay supported following steady execution and confirmation of robust double-digit top-line and EBITDA expansion.
📈 நீண்ட காலம்The hub-and-spoke expansion across non-core geographies (Bengaluru, Pune, and Northeast) aims to replicate Hyderabad's dense, high-margin B2C integrated diagnostics model.
⚠ அபாய எச்சரிக்கைகள்
Geographic concentration risk with Hyderabad still generating ~67% of revenues
Execution and gestation risks across rapid hub additions in competitive non-core metro markets
👀 கவனிக்க வேண்டியவை
Track the ramp-up and margin profile of newly commissioned hubs in Bengaluru and Pune, alongside integration updates from the Arya Wellness acquisition in Guwahati.
Q2 FY27 PAT Rises 37.4% YoY to ₹59.5 Cr; Revenue Up 26.7% to ₹255.4 Cr
Vijaya Diagnostic Centre reported strong Q2 FY27 performance with revenue growing 26.7% YoY to ₹255.4 crore and PAT rising 37.4% YoY to ₹59.5 crore. Operating margins expanded by 355 bps YoY to 44.1%, driven by operating leverage and 16.5% test volume growth. The company also announced entry into the North-East via a Business Transfer Agreement to acquire Arya Wellness Centre in Guwahati. Network expansion continued with 2 hubs and 7 spokes commissioned in FY27 so far, and plans to add 3 hubs and 7 spokes in H2 FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுVijaya reported robust double-digit top-line and profit growth for Q2 FY27 alongside an acquisition agreement in Guwahati marking its North-East expansion.
ஏன் இது முக்கியம்Demonstrates sustained margin strength (>44%) and consistent 20%+ revenue growth while validating geographical diversification beyond its core Hyderabad/RoAPT footprint into West Bengal and Assam.
📅 குறுகிய காலம்The strong operational metrics and margin expansion of 355 bps are likely to be viewed positively in the near term following the earnings concall.
📈 நீண்ட காலம்Expansion into non-core markets (Pune turnaround, West Bengal Tier-II cities, and North-East via Guwahati acquisition) supports long-term volume scalability and lowers geographic concentration risk.
⚠ அபாய எச்சரிக்கைகள்
Geographic concentration remains high with Hyderabad contributing 67% of revenues
Integration and margin dilution risks from new center expansions and North-East entry
👀 கவனிக்க வேண்டியவை
Track the integration and financial contribution of the Arya Wellness acquisition in Guwahati, alongside the planned launch of 3 hubs and 7 spokes in H2 FY27.
Vijaya Diagnostic Q2 Standalone PAT Up 34.8% YoY to ₹57.92 Cr; Revenue Rises 27.4%
Vijaya Diagnostic Centre reported its Q2 FY27 (quarter ended September 30, 2026) standalone results, with revenue from operations growing 27.4% YoY to ₹242.00 crore from ₹189.96 crore. Standalone Profit After Tax rose 34.8% YoY to ₹57.92 crore compared to ₹42.98 crore in Q2 FY26. For H1 FY27, standalone revenue reached ₹460.54 crore and PAT stood at ₹111.07 crore, up from ₹367.33 crore and ₹82.03 crore in H1 FY26 respectively. Additionally, the Board approved the appointment of Mr. Rahul Jain as Company Secretary and Compliance Officer effective November 3, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுVijaya Diagnostic approved and declared its Q2 and H1 FY27 financial results and appointed Rahul Jain as the new Company Secretary and Compliance Officer.
ஏன் இது முக்கியம்Demonstrates robust top-line and bottom-line momentum with standalone revenue growing above the management's historical 15% guidance run-rate.
📅 குறுகிய காலம்Strong YoY earnings growth is likely to support positive market sentiment in the near term.
📈 நீண்ட காலம்Sustained revenue and profit expansion reflects strong operational leverage and network utilization across diagnostic hubs.
⚠ அபாய எச்சரிக்கைகள்
Geographic concentration risks and pace of expansion break-evens in newer non-core markets
👀 கவனிக்க வேண்டியவை
Track the full consolidated performance details and management commentary regarding volume growth, pricing, and expansion progress in Pune and Bengaluru hubs in upcoming earnings calls.
Vijaya Diagnostic to Acquire Guwahati's Arya Wellness for ~₹46 Cr
Vijaya Diagnostic Centre has executed a Business Transfer Agreement (BTA) to acquire 100% of the integrated diagnostic business undertaking of Arya Wellness Centre in Guwahati, Assam, for approximately ₹46 crore via internal accruals. The target generated FY26 revenue of ₹26 crore (INR 260 Mn) with an EBITDA of ₹5.6 crore (INR 56 Mn, 21.4% margin) and PAT of ₹2.5 crore (INR 25 Mn). The transaction is valued at ~8-9x FY26 EBITDA and marks Vijaya's entry into the North-East, expanding its footprint to 7 states and 167 centres upon closing expected by Nov/Dec 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுVijaya Diagnostic entered into a BTA to acquire the diagnostic business of Arya Wellness Centre, marking its entry into Assam.
ஏன் இது முக்கியம்While small financially (~3% of Vijaya's TTM revenue and ~0.3% of market cap), the acquisition provides an established, profitable B2C diagnostic hub to expand its presence into North-Eastern India.
Deal consideration: ~₹46 கோடிDeal value vs Market Cap: ~0.30%Target FY26 Revenue: INR 260 MnTarget FY26 Revenue vs TTM Revenue: ~3.12%Target FY26 EBITDA Margin: 21.4%Expected Closing Timeline: ~Nov / Dec 2026
📅 குறுகிய காலம்Positive sentiment from strategic geographical diversification and an immediately EPS-accretive acquisition at a reasonable valuation of ~8-9x EBITDA.
📈 நீண்ட காலம்Serves as a regional anchor hub in Guwahati to execute hub-and-spoke expansion across Assam and the wider North-East, complementing its Eastern India operations.
⚠ அபாய எச்சரிக்கைகள்
Execution and geographical integration risks outside of its core southern markets
Arya Wellness operates with lower EBITDA margins (21.4%) compared to Vijaya's consolidated OPM (~42%)
👀 கவனிக்க வேண்டியவை
Track the completion of conditions precedent and closing expected by Nov/Dec 2026, followed by integration milestones and margin expansion toward Vijaya's company-level OPM of ~42%.
Vijaya Diagnostic Sets Sep 16, 2026 Record Date for ₹2/Share Final Dividend
Vijaya Diagnostic Centre Limited has fixed Wednesday, September 16, 2026, as the record date for determining shareholder eligibility for its final dividend of ₹2 per equity share (face value ₹1, or 200%) for FY 2025-26. The 24th Annual General Meeting (AGM) will be held via video conferencing on Thursday, September 24, 2026. Remote e-voting runs from September 21 to September 23, 2026. If approved at the AGM, the dividend will be disbursed within 30 days of the meeting.
உச்சம் நம்பிக்கை
என்ன மாறியதுFormalized the record date (Sep 16, 2026) and AGM date (Sep 24, 2026) for payout of the previously recommended FY26 final dividend of ₹2 per share.
ஏன் இது முக்கியம்Provides payout certainty and scheduling for shareholders awaiting the ₹2 per share cash distribution from FY26 profits.
Final dividend per share: ₹ 2முக மதிப்பு: ₹ 1Dividend percentage: 200%ரெக்கார்ட் தேதி: 16-செப்.-2026AGM date: 24-செப்.-2026
📅 குறுகிய காலம்Shares will trade ex-dividend around mid-September 2026 with price adjusting accordingly on the ex-date.
📈 நீண்ட காலம்Limited; reflects standard annual profit distribution and capital return to shareholders.
👀 கவனிக்க வேண்டியவை
Track the ex-dividend date (likely September 15 or 16, 2026) to ensure eligibility, and look out for AGM voting resolutions on September 24, 2026.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
22.8% Revenue Growth in Q1 FY27; Vijaya Plans Rs 195 Cr Capex for 9 New Hubs
Vijaya Diagnostic reported a strong Q1 FY27 with consolidated revenue growing 22.8% YoY to Rs 231 Cr, led by a 16.5% increase in test volumes. EBITDA margins expanded significantly by 360 bps to 42.7%, driven by a high B2C mix (92%) and an integrated radiology-pathology model. The company announced an aggressive expansion plan with a capex of Rs 190-195 Cr (approx. 24% of TTM revenue) to add 9 hubs and 10-12 spokes. Management maintains a long-term growth guidance of 15% CAGR, supported by deepening penetration in Bengaluru and Pune.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a period of consolidation to aggressive expansion, committing ~24% of its TTM revenue toward new capacity in FY27.
ஏன் இது முக்கியம்The integrated 'Pathology + Radiology' model allows for higher realization per patient (Rs 1,860) and superior margins compared to standalone pathology labs. Successful expansion into Bengaluru and Pune will reduce geographic concentration risk.
📅 குறுகிய காலம்Positive sentiment expected due to strong volume growth and margin expansion that outperformed management's own expectations.
📈 நீண்ட காலம்Structural growth is tied to the successful replication of the Hyderabad hub-and-spoke model in Bengaluru and Pune; the high-capex radiology moat remains a key differentiator.
⚠ அபாய எச்சரிக்கைகள்
Geographic concentration (67% revenue from Hyderabad)
Execution risk in new competitive markets
Gestation period of new hubs potentially impacting short-term margins
👀 கவனிக்க வேண்டியவை
Monitor the execution timeline and break-even periods for the 9 new hubs, particularly the flagship Bengaluru facility. Watch if the company can maintain its 40%+ EBITDA margins as it scales outside its core Hyderabad market, which currently contributes 67% of revenue.
22.8% Revenue Growth in Q1 FY27; 9 New Hubs Planned for Next 12 Months
Vijaya Diagnostic reported a strong Q1 FY27 with revenue growing 22.8% YoY to ₹231 Cr and PAT increasing 37.6% to ₹53.1 Cr. The company achieved a robust EBITDA margin of 42.7%, up 356 bps YoY, driven by a 16.5% increase in test volumes and a 12.7% rise in footfalls. Management has guided for aggressive expansion, planning 9 new hub centers and 10-12 spokes over the next 12 months. The flagship JP Nagar hub in Bengaluru was commissioned in July 2026, marking a key step in geographical diversification.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its Q1 FY27 financial results and announced an accelerated expansion plan for the next 12 months.
ஏன் இது முக்கியம்The strong volume growth and margin expansion demonstrate high operational leverage; the aggressive hub expansion targets geographical diversification to reduce the current 67% revenue concentration in Hyderabad.
Q1 FY27 Revenue: ₹231.0 கோடிQ1 வருவாய் vs TTM வருவாய்: 28.8%EBITDA லாப வரம்பு: 42.7%YoY PAT Growth: 37.6%Planned Hub Expansion: 9 யூனிட்கள்Test Volume Growth: 16.5%
📅 குறுகிய காலம்Positive sentiment is expected as the company exceeded its historical 15% growth guidance with 22.8% revenue growth and significant margin improvement.
📈 நீண்ட காலம்The successful rollout of the hub-and-spoke model in Bengaluru and Pune could structurally re-rate the business by proving its scalability beyond its home territory.
⚠ அபாய எச்சரிக்கைகள்
High geographic concentration (67% revenue from Hyderabad)
👀 கவனிக்க வேண்டியவை
Monitor the execution timeline and break-even performance of the 9 planned hub centers, particularly the new flagship JP Nagar hub, to assess the company's success in scaling outside its core Hyderabad market.
22.8% Revenue Growth in Q1 FY27; EBITDA Margins Expand to 42.7% on Strong Volumes
Vijaya Diagnostic reported a robust Q1 FY27 with consolidated revenue growing 22.8% YoY to ₹230.98 Cr, notably surpassing the previous quarter (Q4 FY26) despite Q1 being a seasonally moderate period. Profitability outperformed revenue growth, with PAT rising 37.6% YoY to ₹53.10 Cr and EBITDA margins expanding by 356 bps to 42.7%. Growth was driven by a 16.5% increase in test volumes and a 9.0% improvement in average realization per footfall, supported by the commissioning of new hubs in Hyderabad and Bengaluru.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has delivered a strong earnings beat, exceeding its typical 15% growth guidance with 22.8% revenue growth and significant margin expansion in a seasonally moderate quarter.
ஏன் இது முக்கியம்The results validate the scalability of Vijaya's integrated 'Pathology + Radiology' model and its ability to drive higher realizations through advanced imaging and wellness packages (14.8% share).
📅 குறுகிய காலம்The stock is likely to react positively to the margin expansion and strong volume growth, which indicates robust operational efficiency.
📈 நீண்ட காலம்Structural growth remains supported by the hub-and-spoke expansion strategy; successful penetration into Bengaluru and Pune is critical for maintaining the current high valuation multiples.
⚠ அபாய எச்சரிக்கைகள்
High P/E valuation (80.9) leaves limited room for execution errors
Intense competition in new geographies like Bengaluru and Pune
👀 கவனிக்க வேண்டியவை
Monitor the ramp-up and break-even timeline of the new flagship Bengaluru hub and the four new spokes commissioned in Q1. Investors should watch if the company can maintain these industry-leading 40%+ EBITDA margins as it scales in competitive non-core markets like Pune and Bengaluru.
Vijaya Diagnostic Q1 FY27: Net Profit Surges 36% YoY to ₹53.15 Cr; Revenue Up 23%
Vijaya Diagnostic Centre reported a strong performance for Q1 FY27, with standalone revenue from operations growing 23.2% YoY to ₹218.54 Cr. Net profit for the quarter rose 36.1% YoY to ₹53.15 Cr, significantly outpacing revenue growth. Operational efficiency improved as EBITDA margins reached approximately 47.4%, up from 43.9% in the same quarter last year. The company also integrated the business of Medinova Millennium MRI Services LLP via a slump sale during this period.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its Q1 FY27 financial results, showing significant YoY growth in both revenue and profitability, alongside the accounting integration of its 100% owned subsidiary Medinova Millennium MRI Services LLP.
ஏன் இது முக்கியம்The results demonstrate the company's ability to scale its integrated pathology and radiology model effectively, maintaining high margins despite expansion into new competitive geographies like Bengaluru and Pune.
📅 குறுகிய காலம்The stock is likely to react positively in the short term due to the strong double-digit growth in net profit and significant margin expansion compared to historical averages.
📈 நீண்ட காலம்The company's structural growth remains supported by its high-barrier radiology services and successful hub-and-spoke expansion, though long-term performance depends on maintaining market share in new cities.
⚠ அபாய எச்சரிக்கைகள்
Potential equity dilution from the grant of 179,500 ESOPs
High competitive intensity in expansion markets like Pune
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the 47%+ EBITDA margins and the volume growth contribution from new hubs in Pune and Bengaluru. Watch for the upcoming Annual General Meeting for the final approval of the recommended ₹2 per share dividend.
Vijaya Diagnostic Appoints Narasimha Raju K.A. as CFO, Effective July 09, 2026
Vijaya Diagnostic Centre has appointed Mr. Narasimha Raju K.A. as its Chief Financial Officer, effective July 09, 2026. Mr. Raju is a returning executive who previously served as the company's CFO from March 2021 to March 2025, a period that included the company's successful IPO. With over 20 years of experience in healthcare and diagnostics finance, his return provides leadership continuity as the company targets a 15% CAGR and integrates the Medinova merger. The appointment is significant given the company's high operating margins of 41.6% and ongoing expansion in Pune and Bengaluru.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has re-hired its former CFO, Narasimha Raju K.A., to lead the finance function, replacing the interim or previous leadership.
ஏன் இது முக்கியம்Leadership continuity is vital for a high-growth healthcare firm (22% ROCE). His familiarity with Vijaya's 'Pathology + Radiology' model and previous IPO experience reduces transition risks during the current expansion phase.
Professional Experience: 20+ yearsPrevious Tenure at Vijaya: மார்ச் 2021 to மார்ச் 2025TTM வருவாய்: Rs 802 கோடிOperating Profit Margin: 41.6%
📅 குறுகிய காலம்The market is likely to view the return of a known and experienced CFO as a stabilizing move, supporting the current positive price momentum.
📈 நீண்ட காலம்His expertise in M&A and capital markets is structurally significant as the company integrates Medinova and pursues inorganic growth to maintain its 15% CAGR target.
👀 கவனிக்க வேண்டியவை
Investors should watch for continued stability in financial reporting and the execution of the 15% top-line growth guidance under the returning CFO's leadership.
Vijaya Diagnostic Re-appoints Former CFO Narasimha Raju K.A. with 20+ Years Experience
Vijaya Diagnostic Centre has appointed Mr. Narasimha Raju K.A. as Chief Financial Officer effective July 09, 2026. Mr. Raju is a returning leader who previously served as the company's CFO from March 2021 to March 2025, a period that included the company's IPO. He brings over 20 years of experience in finance and corporate governance, most recently serving as CFO of Yashoda Group of Hospitals. This appointment provides leadership continuity as the company targets a 15% CAGR and integrates the Medinova merger.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has re-hired its former CFO, Mr. Narasimha Raju K.A., to lead its financial operations, replacing the interim or previous incumbent.
ஏன் இது முக்கியம்CFO continuity is vital for a high-margin (41.6% OPM) business. His familiarity with Vijaya's specific 'Pathology + Radiology' model and previous experience with their IPO and capital market transactions reduces operational transition risks.
Professional Experience: 20+ yearsPrevious Tenure at Vijaya: மார்ச் 2021 to மார்ச் 2025TTM வருவாய்: ₹802 கோடிTTM Operating Profit Margin: 41.6%Market Capitalization: ₹14,044 கோடி
📅 குறுகிய காலம்The market is likely to view the return of a proven CFO positively, as it suggests stability and institutional memory during a period of geographic expansion.
📈 நீண்ட காலம்His expertise in M&A and capital markets will be critical as the company integrates Medinova and pursues further inorganic growth to sustain its 15% CAGR target.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's execution on its 15% CAGR guidance and the speed of break-even for new hubs in Pune and Bengaluru under the returning financial leadership.
Vijaya Diagnostic Centre CTO Sai Siva Prasad Resigns; Last Working Day August 08, 2026
Vijaya Diagnostic Centre Limited has announced the resignation of its Chief Technology Officer (CTO), Mr. Sai Siva Prasad, citing personal reasons. The resignation was tendered on June 09, 2026, and he will continue in his role until August 08, 2026, to facilitate a smooth transition. This follows a separate notification regarding the resignation of the CFO, Mr. Ankit Shah, effective July 24, 2026, indicating a period of significant leadership transition within the company's senior management.
முக்கிய அம்சங்கள்
Mr. Sai Siva Prasad resigned as Chief Technology Officer (CTO) effective from the close of business on August 08, 2026.The resignation was officially submitted on June 09, 2026, citing personal reasons for the departure.This management change coincides with the upcoming departure of the company's CFO in July 2026.The company is currently managing the handover process to ensure operational and technological continuity.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to recruit qualified successors for both the CTO and CFO positions to ensure that financial and technological strategies remain uninterrupted.
Vijaya Diagnostic Appoints Two Independent Directors with Pharma and AI Expertise
Vijaya Diagnostic Centre has appointed Mr. Satyanaryana Murthy Chavali and Mr. Dipinder Singh Sekhon as Additional Independent Directors effective May 26, 2026. Mr. Chavali, appointed for a 5-year term, brings deep pharmaceutical leadership experience from his time as CEO of Aurigene Discovery Technologies and senior roles at Dr. Reddy's. Mr. Sekhon, appointed for a 2-year term, is an AI and medical imaging specialist who founded iKITES.ai and Ophthal.ai. These appointments are intended to bolster the board's strategic oversight in healthcare technology and large-scale operations.
முக்கிய அம்சங்கள்
Mr. Satyanaryana Murthy Chavali appointed as Independent Director for a 5-year term starting May 26, 2026.Mr. Dipinder Singh Sekhon appointed as Independent Director for a 2-year term starting May 26, 2026.New directors bring specialized expertise in pharmaceutical R&D, AI-driven medical imaging, and technology entrepreneurship.Appointments are subject to shareholder approval and comply with SEBI Listing Regulations.
👀 கவனிக்க வேண்டியவை
Investors should view these appointments as a positive move to strengthen board-level expertise in AI and pharma, which could drive future diagnostic innovations. No immediate portfolio action is required.
Vijaya Diagnostic reported a strong Q4 FY26 with revenue growing 26.6% YoY to ₹219 crores, driven by an 18.5% increase in test volumes. The company achieved a significant milestone as full-year FY26 revenue crossed ₹800 crores, reaching ₹814 crores with a robust EBITDA margin of 41.4%. Profitability improved significantly with Q4 PAT rising 37.5% YoY to ₹47.9 crores. Management plans to continue aggressive expansion in FY27 with 4-5 new hubs and a state-of-the-art automated lab in Hyderabad.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue grew 26.6% YoY to ₹219 crores, supported by 18.5% volume growthEBITDA margins expanded by 379 bps YoY to 43.5% in Q4 FY26Full-year FY26 revenue reached ₹814 crores, delivering a 5-year CAGR of 17%Planned FY27 capex of ₹140-₹150 crores for 4-5 hubs and 10-12 spokesB2C segment remains dominant, contributing 92% of total revenue
👀 கவனிக்க வேண்டியவை
Investors should view the strong volume growth and margin expansion as a sign of high operational efficiency and brand strength. The stock remains a solid pick in the diagnostic space given its B2C focus and disciplined expansion strategy.
Vijaya Diagnostic Q4 PAT Surges 37.5% YoY to ₹47.9 Cr; FY26 Revenue Crosses ₹800 Cr
Vijaya Diagnostic reported a robust Q4 FY26 with revenue growing 26.6% YoY to ₹219.4 crore, driven by strong 18.5% volume growth in tests. The company achieved its highest-ever quarterly revenue and maintained a superior EBITDA margin of 43.5%, up from 39.8% in the previous year. For the full year FY26, revenue reached ₹814.2 crore, marking a 19.5% growth, while PAT rose 20.3% to ₹173 crore. The company continues to maintain a high B2C revenue share of 92% and is aggressively expanding its footprint in Bengaluru and West Bengal.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue grew 26.6% YoY to ₹2,194 Mn with EBITDA margins expanding 379 bps to 43.5%.Full-year FY26 PAT increased by 20.3% to ₹1,730 Mn, surpassing the company's long-term growth guidance.B2C segment remains the core strength, contributing 92% of total revenue with footfalls rising 15.8% in Q4.Wellness segment showed significant momentum, growing 32.2% YoY in Q4 FY26.Expansion plans for FY27 include adding 4-5 new hubs and 10-12 spokes to deepen presence in non-core markets.
👀 கவனிக்க வேண்டியவை
Vijaya Diagnostic demonstrates industry-leading margins and strong cash flow generation from its B2C-heavy model. Investors should view the consistent volume growth and successful break-even of new hubs as positive indicators for long-term scalability.
Vijaya Diagnostic Recommends ₹2 Dividend and Acquires Subsidiary Business for ₹4.20 Cr
Vijaya Diagnostic Centre has recommended a final dividend of ₹2 per share (200% of face value) for FY 2025-26. The company is consolidating its operations by acquiring the MRI, EEG, and NCV services business from its wholly-owned subsidiary, Medinova Millennium MRI Services LLP, for approximately ₹4.20 crore. Additionally, the board approved the grant of 1,79,500 ESOPs at an exercise price of ₹784 per share to eligible employees. Independent Director Dr. D Nageshwar Reddy will step down effective May 25, 2026, following the completion of his five-year term.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹2 per equity share (200% on face value of ₹1) for FY26.Acquisition of diagnostic services business from subsidiary Medinova Millennium for ~₹4.20 crore.Grant of 1,79,500 ESOPs at ₹784 per share, representing a 20% discount to the 3-month average price.Medinova Millennium MRI Services LLP reported a turnover of ₹2.36 crore for the financial year 2025-26.Independent Director Dr. D Nageshwar Reddy to cease office on May 25, 2026, due to professional commitments.
👀 கவனிக்க வேண்டியவை
Investors should benefit from the ₹2 per share dividend and the operational streamlining through the subsidiary business acquisition. The ESOP grant at a discount suggests a focus on long-term employee alignment with company growth.
Vijaya Diagnostic Centre has recommended a final dividend of ₹2 per share (200% of face value) for the financial year ended March 31, 2026. The board approved the grant of 179,500 ESOPs at an exercise price of ₹784, which includes a 20% discount to the recent average market price. Additionally, the company is consolidating its operations by acquiring the MRI and EEG services business from its wholly-owned subsidiary, Medinova Millennium MRI Services LLP, for approximately ₹4.20 crore. Independent Director Dr. D Nageshwar Reddy will retire on May 25, 2026, following the completion of his first term.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹2 per equity share (200% of face value ₹1) for FY 2025-26.Granted 179,500 ESOPs at an exercise price of ₹784 per share with a 10-year exercise period.Acquiring MRI, EEG, and NCV services business from subsidiary Medinova Millennium for ~₹4.20 crore.Independent Director Dr. D Nageshwar Reddy to step down on May 25, 2026, due to professional commitments.The internal acquisition is expected to be completed within 3 months to streamline healthcare service delivery.
👀 கவனிக்க வேண்டியவை
Investors should benefit from the ₹2 dividend and the operational streamlining through the internal acquisition. Monitor the company's growth trajectory following the consolidation of its subsidiary's diagnostic services.
Vijaya Diagnostic Q3 FY26: Record Revenue of ₹205 Cr, EBITDA Margins Expand to 41.9%
Vijaya Diagnostic reported its highest-ever quarterly revenue of ₹205 crores in Q3 FY26, marking a robust 21.4% YoY growth driven by a 14.7% increase in test volumes. Profitability showed significant improvement with EBITDA rising 28.2% YoY to ₹86 crores, while EBITDA margins expanded by 221 basis points to reach 41.9%. The company successfully expanded its footprint with four new hubs during the quarter, including two in West Bengal where early launches have already achieved breakeven within three quarters. Management maintains a strong balance sheet with a net surplus cash of ₹260 crores and has planned a capex of ₹100-120 crores for FY27 to fuel further expansion.
முக்கிய அம்சங்கள்
Highest ever quarterly revenue of ₹205 crores, up 21.4% YoY with 14.7% volume growthEBITDA margins expanded by 221 bps YoY to 41.9%, with PAT growing 22.3% to ₹43 croresCore Hyderabad market grew 15% YoY, while West Bengal expansion showed early success with 3-quarter breakevensStrong liquidity position with net surplus cash of ₹260 crores as of December 31, 2025Planned FY27 capex of ₹100-120 crores focusing on 4-5 new hubs and 10-12 spokes
👀 கவனிக்க வேண்டியவை
Investors should view the strong margin performance and rapid breakeven in new territories as a sign of efficient scaling. The stock remains attractive given its robust B2C mix and significant cash reserves for future growth.
Vijaya Diagnostic Appoints New CFO, COO, and CTO; Grants 1.15 Lakh ESOPs
Vijaya Diagnostic Centre has announced a major leadership restructuring, appointing Mr. Ankit Shah as the new Chief Financial Officer effective February 13, 2026. The company also strengthened its executive team by appointing Mr. Sai Prasad as CTO and Mr. Venkata Siva Rama Raju Vegesna as COO to drive digital and operational growth. Additionally, the board approved the grant of 1,15,000 ESOPs and the appointment of two new Independent Directors for five-year terms. The outgoing CFO, Mr. S. Ramachandra Reddy, will transition to a General Manager role within the finance department.
முக்கிய அம்சங்கள்
Mr. Ankit Shah appointed as CFO, bringing 20+ years of experience in healthcare finance and M&A.New CTO and COO roles filled to lead digital transformation and operational strategy.Grant of 1,15,000 ESOPs approved under the VDCL Employee Stock Option Plan 2018.Two Independent Directors appointed for 5-year terms, strengthening board governance.Outgoing CFO Mr. S. Ramachandra Reddy remains with the company as GM - Finance & Accounts.
👀 கவனிக்க வேண்டியவை
Investors should view this management refresh as a move toward professionalizing the leadership for the next phase of growth. Monitor the execution of digital initiatives under the new CTO and operational efficiencies under the new COO.
Vijaya Diagnostic Announces Major Management Overhaul and Grant of 1.15 Lakh ESOPs
Vijaya Diagnostic Centre has announced a significant leadership restructuring, including the appointment of a new CFO (Ankit Shah), COO (Venkata Siva Rama Raju Vegesna), and CTO (Sai Prasad). The board also approved the grant of 1,15,000 ESOPs under its 2018 plan, which are convertible into an equivalent number of equity shares. Alongside these executive changes, two new Independent Directors with legal and medical expertise have been appointed for five-year terms. These announcements were made following the board's approval of the Q3 and nine-month financial results for FY26.
முக்கிய அம்சங்கள்
Grant of 1,15,000 Employee Stock Options (ESOPs) convertible into equity shares of ₹1 face value each.Appointment of Ankit Shah as Chief Financial Officer, succeeding S. Ramachandra Reddy who moves to a GM role.Venkata Siva Rama Raju Vegesna appointed as COO, bringing experience from KIMS Hospitals and previous tenure at Vijaya.Appointment of two new Independent Directors, Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola, for 5-year terms.New Chief Technology Officer (Sai Prasad) appointed to lead digital transformation and IT strategy.
👀 கவனிக்க வேண்டியவை
Investors should monitor the impact of the new leadership team on the company's operational execution and strategic growth, while also reviewing the Q3 FY26 financial performance.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
